INTRODUCTION {#sec1-1}
============

Isatin (1-H indole 2-3 dione) are synthetically versatile substances that are employed for the synthesis of a large variety of heterocyclic compounds, including some drugs. Over the years, the molecules with isatin show diversified biological activities, e.g. antibacterial,\[[@CIT1]\] anticonvulsants,\[[@CIT2]\] antiviral\[[@CIT3]\] and antitubercular\[[@CIT4]\] activities. Schiff and mannich bases of isatin have shown good antimicrobial activities against gram-negative bacteria and fungi.\[[@CIT3]\] A number of Spiro compounds derived from isatin are important pharmacophores and exhibit promising biological activities,\[[@CIT5]\] such as analgesic, fungicidal and anti-inflammatory activity. Thiazole and its derivatives are reported to show good antibacterial, anti-inflammatory and analgesic\[[@CIT6]\] activity. Hence, it was thought worthwhile to synthesize new Schiff, mannich and Spiro isatin derivatives and investigate them for biological and pharmacological activities. The key starting materials, 1-H-indole 2-3 dione and 2-aminothiazole, were refluxed in the presence of alcohol and glacial acetic acid to get Schiff base 3 (1'-3'thiazole 2-yl imino) 1-3 dihydro 2-H-indole-2-one (A); mannich bases are prepared with different secondary amines in the presence of formaldehyde (A~1~ -A~6~). Meanwhile, Spiro isatin derivatives are prepared with Azetidine (A~a~) and thiazolidone (A~b~) in the presence of chloroacetyl chloride (Cl-CH~2~ -CO-Cl) and thioglycolic acid (SH-CH~2~ -COOH).

MATERIALS AND METHODS {#sec1-2}
=====================

Melting points are recorded in open capillary tubes and are uncorrected. The IR spectra (KBr) were recorded on a SHIMADZU FTIR-8300, spectrophotometer, Japan. The H-NMR spectra were recorded on a Bruker Advance-400 MHz spectrometer, USA. Purity of the compounds was checked by Thin layer chromatography For analgesic, anti-inflammatory activity studies, adult healthy albino rats (Swiss strain) of either sex weighing 80--120 g were used. All the animals were maintained under standard conditions and had access to pelleted animal feed and water. The study protocol was approved by the Institutional Animal Ethics Committee.

Synthesis\[[@CIT7]\] of 3(1'-3'Thiazole-2-yl Imino) 1-3 Dihydro-2H Indole-2-One (A) {#sec2-1}
-----------------------------------------------------------------------------------

Equimolar quantity of isatin and 2-amino thiazole was taken in a round bottom flask, dissolving the content with a sufficient amount of ethanol and two to three drops of glacial acetic acid was added. The content was refluxed for 4--5 h and then poured into ice cold water. The solid obtained was filtered, dried and recrystallized from ethanol.

Synthesis\[[@CIT7]\] of 1\[(Diphenyl Amino) Methyl\]-3-(1'-3' Thiazole-2-yl Imino) 1-3 Dihydro-2H Indole-2-One (A~1~) {#sec2-2}
---------------------------------------------------------------------------------------------------------------------

To a slurry containing A (0.003 mol), ethanol (5 ml) and 37% formalin (1 ml), diphenylamine (0.003 mol) was added slowly with good stirring. The reaction mixture was cooled and allowed to stand at room temperature for 1 h, with occasional shaking. Then, it was warmed on a steam bath for 15 min, cooled and the product was recovered. The product was recrystallized from chloroform--methanol (1:1) mixture.

The compounds 1(piperazin-1-yl) methyl-3-(1'-3' thiazole-2-yl imino) 1-3 dihydro-2H indole-2-one (A~2~), 1\[(dicyclohex-yl) methyl\]-3-(1'-3' thiazole-2-yl imino) 1-3 dihydro-2H indole-2 one (A~3~), 1\[(dimethylamino) methyl\]-3-(1'-3' thiazole-2-yl imino) 1-3 dihydro-2H indole-2 one (A~4~), 1-\[(diethylamino) methyl\]-3-(1'-3' thiazole-2-yl imino) 1-3 dihydro-2H indole-2 one (A~5~) and 1-\[(morpholin-4"yl) methyl\]-3-(1'-3' thiazole-2-yl imino) 1-3 dihydro-2H indole-2 one (A~6~) were prepared by following a similar procedure.

Synthesis of 3'Chloro-1-(1"-3"Thiazo-2-yl) 4'-H-Spiro \[Azetidine-2, 3'Indole\] 2'4-(1-H) Di One (A~a~)\[[@CIT8]\] {#sec2-3}
------------------------------------------------------------------------------------------------------------------

Compound 3(1'-3'thiazole-2-yl imino) 1-3dihydro-2H indole-2-one (A) (0.01mol) was dissolved in 1-4 dioxan (20 ml) in a 100 ml beaker and trimethyl amine (0.001 mol) was added to it. Then, the contents of the beaker were stirred and chloroacetyl chloride (0.001 mol) was added slowly, continuing stirring of contents of the beaker for 8 h. The resulting solution was poured into ice cold water, filtered, dried, recrystallized from chloroform--methanol (1:1) and added in a round bottom flask. The content of the flask was refluxed for 12--14 h, the product was recovered in ice cold water, filtered, dried and finally recrystallized from chloroform--methanol (1:1) mixture.

Synthesis of 3'Chloro-1-(1"-3"Thiazo-2-yl) 4'-H-Spiro \[Indole-3,2-(1,3) Thiazolidine\] 2'4-(1-H) Di One (A~B~)\[[@CIT5]\] {#sec2-4}
--------------------------------------------------------------------------------------------------------------------------

Equimolar quantity of compound A and thioglycollic acid was dissolved in a round bottom flask. Then, 1,4-dioxane and a pinch of zinc chloride was added to it. The contents of the mixture were refluxed for 12--14 hr, concentrating the content of the flask, and poured into ice cold water. The solid mass was collected and dried. The product was recrystallized from chloroform--methanol mixture (1:1).

Antimicrobial activity {#sec2-5}
----------------------

The *in vitro* antimicrobial activity\[[@CIT9]\] was carried out against 24-h-old cultures of microorganisms by the cup--plate method. Compound A~1~ -A~6~and A~a~, A~b~were tested against four pathogenic bacteria, *Pseudomonas mirebelis, Pseudomonas auroginosa, Escherichia* coli and *Staphylococcus aureus*. The antifungal activity was tested against *Aspergillus niger* and *Candida albicans*. Ampicillin and cotrimoxazole was taken as an internal standard for antibacterial and antifungal activity, respectively. The compound was tested at a concentration of 100 µ/ml in DMF against all organisms. The zone of inhibition was compared with the standard drug after 24-h incubation at 37°C for antibacterial and 48 h at 25°C for antifungal activity.

Analgesic activity {#sec2-6}
------------------

The analgesic activity\[[@CIT10]\] was evaluated by the acetic acid-induced writhing test\[[@CIT6]\] using adult Swiss albino mice of either sex. In this method, mice are made to writhe by a simple intraperitonial injection of 0.6% v/v aqueous acetic acid (0.1 ml/kg). Test substances were administered 30 min before the injection of acetic acid. The number of writhes (full extension of hind paws) was recorded.

Anti-inflammatory activity {#sec2-7}
--------------------------

The anti-inflammatory activity\[[@CIT10]\] was evaluated by rat paw edema. Edema represents the early phase of inflammation and carragenin-induced paw edema is the simplest and most widely used method\[[@CIT8]\] for studying the anti-inflammatory activity of the chemical compounds. This method is based on the plethysmographic measurement of carragenin-induced acute rat paw edema. For this study, Wister rats of either sex, weighing between 80 and 100 g were divided into 10 groups of five animals each. Group1 serves as a solvent control, and received 0.5% Carboxy Methyl Cellulose in normal saline orally. Group 2 received indomethacin (10 mg/kg) in solvent as a standard. Groups 3--10 received test drugs at a dose of 100 mg/kg orally. These drugs were administered 1 h before the injection of an irritant, carragenin. After 1 h, all the animals were injected subcutaneously with a suspension of carragenin in CMC solution (0.1 ml) to the left hind paw in the subplantar region and the paw volume was measured immediately. After 3 h, the paw volume was measured for the control, standard and test groups. Percentage inhibition of paw volume was calculated.

RESULTS AND DISCUSSION {#sec1-3}
======================

The structures of newly synthesized compounds were elucidated by IR, ^1^H-NMR and elemental analysis and are reported as follows:

The IR spectrum of **A** in KBr (in cm^-1^): 3446 (NH str), 1728 (C=O), 1610.95 (C=N), 1469.01 (CH=CH of Ar), 1096.66 (C-S-C).

^1^H-NMR of **A** (δ values):11.04 (S, 1H, NH), 6.89--7.61 (m, Ar-H), 3.39 (1H,CH), 3.16 (1H, CH).

IR of **A~1~**(in cm^-1^): 2890 (CH~2~), 1730 (C=O), 1670 (C=N), 1459.37 (CH=CH), 1200 (C-N), 1090 (C-S-C), 766.888 (C=C aromatic hydrocarbon).

^1^H-NMR of A~1~ (δ values): 6.89--7.09 (m, Ar-H), 2.50 (S.2H, N-CH~2~), 3.38 (S, 2H, CH of thiazole).

IR of **A~2~**(in cm^-1^): 2832 (CH~2~), 1720 (C=O), 1609 (C=N), 1480 (CH=CH), 1363 (C-N), 1164.30 (C-S-C str), 3305 (N-H).

^1^H-NMR of **A**~2~ (δ values): 6.89--7.92 (m, Ar-H), 4.38 (S, 1H, N-H), 3.06--3.38 (δ, 1H, CH), 1.23 (t, 2H, CH~2~piperazine).

IR of **A~3~**(in cm^-1^): 2946 (CH), 2854 (C-H), 1718.84 (C=O), 1647.58 (C-N), 1517 (C=N), 1458 (CH=CH of Ar), 1105 (C-S-C).

IR of **A~5~**(in cm^-1^): 2942 (CH~2~), 1735 (C=O), 1676 (C=N), 1654 (C-N), 1542 (CH=CH of Ar), 1042 (C-S-C str), 758 (C=C).

IR of **A~6~**(in cm^-1^): 2396 (CH~2~str), 1718 (C=O), 1560 (C-N str), 1654 (C=N), 1542 (CH=CH of Ar), 1108 (C-S-C str), 1005 (C-O-C str), 717 (C=C Ar).

IR of **A~a~**(in cm^-1^): 3445 (NH str), 1720 (C=O), 1710 (C=O), 1640 (C-N), 649 (C-Cl).

^1^H-NMR **A~a~**: 11.08 (s, 1H, NH), 6.93--7.79 (m-Ar-H), 3.39 (δ,1H, CH of thiazole), 2.27 (s, 1H, CH, CH~2~Cl).

IR of A~b~(in cm^-1^): 3442 (NH str), 1724 (C=O), 1708 (C=O), 1645 (C-N), 1090 (C-S-C).

^1^H-NMR of **A~b~** (δ values): 11.08 (s, 1H, NH), 6.71--7.78 (m-Ar-H), 3.39 (δ, 1H, CH of thiazole), 2.50 (s, 2H, CH~2~).

The characterization of synthesized compounds is given in [Table 1](#T0001){ref-type="table"}. Analytical data of the compounds supports the proposed structures.

###### 

Characterization data of the synthesized compounds

  Compounds   M.P (°C)   Yield%   Molecular formula      Found (calculated) %                 
  ----------- ---------- -------- ---------------------- ---------------------- ------------- ---------------
  A~1~        108--110   59       C~24~H~18~N~4~OS       58.52 (58.72)          5.03 (5.23)   21.12 (21.39)
  A~2~        238--240   68       C~16~H~17~N~5~OS       69.90 (70.22)          4.21 (4.41)   13.40 (13.65)
  A~3~        110--114   72       C~24~H~30~N~4~OS       67.01 (68.21)          6.89 (7.16)   12.89 (13.28)
  A~4~        220--223   72       C~14~H~14~H~4~OS       58.60 (58.72)          4.81 (4.93)   19.40 (19.57)
  A~5~        252--254   61       C~16~H~18~N~4~OS       61.01 (61.12)          5.72 (5.77)   17.81 (17.82)
  A~6~        248--250   65       C~16~H~16~N~4~O~2~S    58.71 (58.82)          4.80 (4.91)   16.99 (17.06)
  A~a~        343--344   65       C~13~H~8~N~3~SO~2~Cl   50.88 (51.47)          2.47 (2.64)   13.53 (13.74)
  A~b~        340--342   62       C~13~H~9~N~3~S~2~O     51.12 (51.47)          2.83 (2.99)   3.63 (13.85)

Results of antimicrobial activity, analgesic activity and anti-inflammatory activity are shown in Tables [2](#T0002){ref-type="table"}--[4](#T0004){ref-type="table"}, respectively. The results of the antimicrobial activity revealed that the compounds A~3~, A~5~, A~6~, A~a~and A~b~ were found to be active against bacteria and fungi. The compounds A~3~, A~6~, A~a~ and A~b~ showed significant analgesic activity, with percentage of inhibition of 43.69, 49.81, 67.51, 64.78, respectively, as compared to indomethacin, with percentage inhibition of 79.56. The compounds A~a~, A~6~, A~b~, showed considerable anti-inflammatory activity, having percentage protection of 38.77, 32.65 and 36.73 as compared with indomethacin, having percentage protection value of 46.93.

Thus, it is observed that the synthesized compounds showed promising antimicrobial, analgesic and anti-inflammatory activities. Further studies are needed to discover new novel compounds of this class with profound activities.

###### 

Results of antimicrobial activity

  Compounds          Zone of inhibition[\*](#T000F1){ref-type="table-fn"} (mm)                              
  ------------------ ----------------------------------------------------------- ------ ------ ----- ------ ------
  A~1~               12                                                          14.2   10     9.5   22.2   17.3
  A~2~               13                                                          12.9   10     8.3   21     16.5
  A~3~               10                                                          10.3   11.2   9.8   23     20
  A~4~               11.1                                                        11     10     8.8   17     17.8
  A~5~               11                                                          11.2   13.6   9.3   21     15.3
  A~6~               12.2                                                        12.5   14     9.1   22.9   19
  A~a~               15.2                                                        17     20     10    5      21.2
  A~b~               13.5                                                        16.1   17.5   10    24.3   20
  Ampicillin         23                                                          22.5   24     26    27.6   28
  Cotrimox zoleDMF   \-                                                                 \-     \-    \-     \-

average of three readings.

###### 

Analgesic activity of the compounds

  Compound code   Dose (mg/kg)   Number of writhing movements                      \% of protection
  --------------- -------------- ------------------------------------------------- ------------------
  0.5% CMC        \-             58.8 ± 0.95                                       -79.5632.1128.46
  Indomethacin    10             11.2 ± 4.32[\*\*](#T000F3){ref-type="table-fn"}   43.7933.2127.91
  A~1~            100            37.2 ± 3.21[\*](#T000F2){ref-type="table-fn"}     49.8167.5164.78
  A~2~            100            39.2 ± 3.48                                       
  A~3~            100            30.8 ± 2.23[\*](#T000F2){ref-type="table-fn"}     
  A~4~            100            36.6 ± 2.97[\*](#T000F2){ref-type="table-fn"}     
  A~5~            100            39.5 ± 3.27                                       
  A~6~            100            27.5±2.85[\*\*](#T000F3){ref-type="table-fn"}     
  A~a~            100            17.8 ± 2.19[\*\*](#T000F3){ref-type="table-fn"}   
  A~b~            100            19.3 ± 2.98[\*\*](#T000F3){ref-type="table-fn"}   

Values are expressed as mean ± SE (*n* = 6).

*P*\<0.05,

*P*\<0.01 and \*\*\**P*\<0.001 compared with vehicle control (ANOVA followed by Dunnet's *t*-test).

###### 

Anti-inflammatory activity of the compounds

  Compound code   Group   Volume of mercury displaced (ml)                                                                                    
  --------------- ------- ---------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------
  0.5% CMC        1       0.49 ± 0.013                                               0.55 ± 0.033                                             0.59 ± 0.022
  Indomethacin    2       0.26 ± 0.012 (46.93)                                       0.37 ± 0.022 (32.72)                                     0.39 ± 0.012 (33.89)
  A~1~            3       0.41 ± 0.025[\*](#T000F4){ref-type="table-fn"} (16.32)     0.54 ± 0.029 (1.81)                                      0.45 ± 0.022[\*\*](#T000F5){ref-type="table-fn"} (23.72)
  A~2~            4       0.48 ± 0.041 (2.02)                                        0.54 ± 0.012 (1.81)                                      0.57 ± 0.032 (3.38)
  A~3~            5       0.32 ± 0.041[\*\*](#T000F5){ref-type="table-fn"} (34.69)   0.53 ± 0.034 (3.36)                                      0.46±0.030[\*\*](#T000F5){ref-type="table-fn"} (22.03)
  A~4~            6       0.47 ± 0.033 (4.08)                                        0.52 ± 0.036 (5.54)                                      0.43±0.032[\*\*](#T000F5){ref-type="table-fn"} (27.11)
  A~5~            7       0.46 ± 0.043 (6.12)                                        0.54 ± 0.012 (1.81)                                      0.56 ± 0.032 (1.69)
  A~6~            8       0.33 ± 0.032[\*\*](#T000F5){ref-type="table-fn"} (32.65)   0.39±0.031[\*](#T000F4){ref-type="table-fn"} (29.09)     0.46±0.016[\*\*](#T000F5){ref-type="table-fn"} (22.03)
  A~a~            9       0.30 ± 0.043[\*\*](#T000F5){ref-type="table-fn"} (38.77)   0.37±0.013[\*\*](#T000F5){ref-type="table-fn"} (32.72)   0.45±0.041[\*\*\*](#T000F6){ref-type="table-fn"} (23.72)
  A~b~            10      0.31 ± 0.041[\*\*](#T000F5){ref-type="table-fn"} (36.73)   0.38±0.033[\*\*](#T000F5){ref-type="table-fn"} (30.90)   0.46±0.061[\*\*](#T000F5){ref-type="table-fn"} (22.03)

Values are expressed as mean ± SE (n = 6).

*P*\<0.05

*P*\<0.01

*P*\<0.001 compared with vehicle control (ANOVA followed by Dunnet's *t*-test).

The authors are thankful to the management of the Institute of Pharmacy and Technology, Salipur, for providing the experimental facilities. The authors also extend their thanks to Dr. Ranjan Mukherjee and Dr. S. N. Meyyanathan of J.S.S College of Pharmacy, Ooty, for carrying out ^1^H-NMR and IR spectral analysis of the compounds.

**Source of Support:** Nil

**Conflict of Interest:** None declared.
